ICAAC 2013: Researchers Present Data on New NNRTIs AIC292 and MK-1439
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 17 September 2013 00:00
- Written by Liz Highleyman
A pair of next-generation HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) demonstrated promising activity in early studies, researchers reported last week at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver. AIC292 showed good antiviral activity in early laboratory, animal and human studies. MK-1439, now in Phase 2b, is likely to interact with ritonavir, but not tenofovir.
ICAAC 2013: Interferon Response Reduces Liver Disease and Death in HIV/HCV Coinfected
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 17 September 2013 00:00
- Written by Liz Highleyman
Effective interferon-based therapy that produces sustained virological response (SVR) led to significant reductions in liver decompensation, HIV disease progression, and both overall and liver-related mortality among HIV/HCV coinfected patients, according to a presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver.
ICAAC 2013: Dolutegravir Shows Good Efficacy Across Patient Groups
- Details
- Category: Approved HIV Drugs
- Published on Monday, 16 September 2013 00:00
- Written by Liz Highleyman
The new integrase inhibitor dolutegravir (Tivicay) worked better than boosted darunavir for people starting HIV treatment for the first time, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver. Another study found that dolutegravir worked well across sex, race/ethnicity, and age groups.
ICAAC 2013: Novel Therapeutic Vaccine Reduces Genital Herpes Shedding
- Details
- Category: Herpes
- Published on Tuesday, 17 September 2013 00:00
- Written by Genocea Biosciences
An experimental immune-modulating vaccine significantly reduced shedding of herpes simplex virus type 2 (HSV-2) in people with recurrent genital herpes, according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver. The vaccine appeared safe and well-tolerated.
ICAAC 2013: New Tenofovir Formulation Has Less Effect on Kidneys and Bones
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 13 September 2013 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF), a new formulation that reaches higher levels in cells but allows for lower dosing, was as effective as the current tenofovir disoproxil fumarate (TDF) formulation but had less impact on markers of kidney function and bone turnover, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.
More Articles...
- Coverage of 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy
- ICAAC 2013: Raltegravir Safest for HIV+ Patients on Cancer Chemotherapy
- ICAAC 2013: Many Truvada PrEP Users Are Women and Young People, Survey Finds
- ICAAC 2013: CD4 Cell Gene Therapy May Enable Functional Control of HIV Off Treatment
Web Design and Development by